AnaptysBio Inc ANAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Anaptys Announces Participation in September Investor Conferences
-
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
-
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
-
Anaptys Sees Positive Trial Results for Imsidolimad Psoriasis Treatment
Trading Information
- Previous Close Price
- $34.81
- Day Range
- $34.51–35.82
- 52-Week Range
- $13.36–41.31
- Bid/Ask
- $25.00 / $35.96
- Market Cap
- $1.06 Bil
- Volume/Avg
- 1 / 318,731
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 30.80
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 117
- Website
- https://www.anaptysbio.com
Comparables
Valuation
|
Metric
|
ANAB
|
MGNX
|
CGON
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 97.20 | 3.83 | 4.39 |
Price/Sales | 30.80 | 5.57 | 242.53 |
Price/Cash Flow | — | — | — |
Price/Earnings
ANAB
MGNX
CGON
Financial Strength
|
Metric
|
ANAB
|
MGNX
|
CGON
|
|---|---|---|---|
Quick Ratio | 8.90 | 2.53 | 46.66 |
Current Ratio | 9.09 | 2.71 | 47.57 |
Interest Coverage | −6.09 | −128.87 | — |
Quick Ratio
ANAB
MGNX
CGON
Profitability
|
Metric
|
ANAB
|
MGNX
|
CGON
|
|---|---|---|---|
Return on Assets (Normalized) | −30.08% | −59.21% | −15.24% |
Return on Equity (Normalized) | −166.16% | −120.96% | −26.61% |
Return on Invested Capital (Normalized) | −130.73% | −102.88% | −25.60% |
Return on Assets
ANAB
MGNX
CGON
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Vrqtphclb | Vqbtc | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pyvbvdgdt | Lnnqrc | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pkdbkbrh | Kgfgtbl | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xfwcqgwhx | Nwmwwk | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Xxkqddn | Sxf | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Gmznfgcs | Wrzg | $28.3 Bil | |||
| Moderna Inc
MRNA
| Hbtdwrcy | Zlyzg | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Ncftdbrl | Bthr | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lmjvbtsv | Lvskd | $13.3 Bil | |||
| Incyte Corp
INCY
| Wlsntfw | Mrqgl | $13.0 Bil |
United States